25





#### Attorney Docket No. 03806.0537

#### **CLAIMS**

- An isolated nucleic acid comprising any one of SEQ ID NOs: 1-4, or a complementary nucleotide sequence thereof.
- 2. An isolated nucleic acid comprising at least eight consecutive nucleotides of a nucleotide sequence of any one of SEQ ID NOs: 1-4, or a complementary nucleotide sequence thereof.
  - 3. An isolated nucleic acid comprising at least 80% nucleotide identity with a nucleic acid comprising any one of SEQ ID NOs: 1-4, or a complementary nucleotide sequence thereof.
  - 4. The isolated nucleic acid according to claim 3, wherein the nucleic acid comprises an 85%, 90%, 95%, or 98% nucleotide identity with the nucleic acid comprising any one of SEQ ID NOs: 1-4, or a complementary nucleotide sequence thereof.
- 5. An isolated nucleic acid that hybridizes under high stringency conditions with a nucleic acid comprising any one of SEQ ID NOs: 1-4, or a complementary nucleotide sequence thereof.
  - 6. An isolated nucleic acid comprising a nucleotide sequence as depicted in any one of SEQ ID NOs: 1-4, or of a complementary nucleotide sequence thereof.
- 7. A nucleotide probe or primer specific for the ABCA12 gene, wherein the nucleotide probe or primer comprises at least 15 consecutive nucleotides of a nucleotide sequence of any one of SEQ ID NOs: 1-4, or of a complementary nucleotide sequence thereof.
  - 8. A nucleotide probe or primer specific for the ABCA12 gene, wherein the nucleotide probe or primer comprises a nucleotide sequence of any one of SEQ ID NO: 7-38, or a complementary nucleotide sequence thereof.
  - 9. The nucleotide probe or primer according to any of claim 7 or 8, wherein the nucleotide probe or primer comprises a marker compound.
  - 10. A method of amplifying a region of the nucleic acid according to claim 1, wherein the method comprises:
- a) contacting the nucleic acid with two nucleotide primers, wherein the first nucleotide primer hybridizes at a position 5' of the region of the nucleic acid, and the

30




# Attorney Docket No. 03806.0537

second nucleotide primer hybridizes at a position 3' of the region of the nucleic acid, in the presence of reagents necessary for an amplification reaction; and

- b) detecting the amplified nucleic acid region.
- 11. A method of amplifying a region of the nucleic acid according to claim 10, wherein the two nucleotide primers are selected from the group consisting of
  - a) a nucleotide primer comprising at least 15 consecutive nucleotides of a nucleotide sequence of any one of SEQ ID NOs: 1-4, or of a complementary nucleotide sequence,
- b) a nucleotide primer comprising a nucleotide sequence of any one of SEQ ID NOs: 7-38, or a complementary sequence thereof.
  - 12. A kit for amplifying the nucleic acid according to claim 1, wherein the kit comprises:
  - a) two nucleotide primers whose hybridization position is located respectively 5' and 3' of the region of the nucleic acid; and optionally,
- b) reagents necessary for an amplification reaction.
  - 13. The kit according to claim 12, wherein the two nucleotide primers are selected from the group consisting of
  - a) a nucleotide primer comprising at least 15 consecutive nucleotides of a nucleotide sequence of any one of SEQ ID NOs: 1-4, or of a complementary nucleotide sequence,
  - b) a nucleotide primer comprising a nucleotide sequence of any one of SEQ ID NOs: 7-38, or a complementary sequence thereof.
  - 14. A method of detecting a nucleic acid according to claim 1, wherein the method comprises:
- a) contacting the nucleic acid with a nucleotide probe selected from the group consisting of
  - 1) a nucleotide probe comprising at least 15 consecutive nucleotides of a nucleotide sequence of any one of SEQ ID NOs: 1-4, or a complementary nucleotide sequence thereof,
    - 2) a nucleotide probe as in any one of claims 7-9,
  - 3) a nucleotide probe comprising a nucleotide sequence of any one of SEQ ID NOs: 7-38, or a complementary nucleotide sequence thereof, and

25






## Attorney Docket No. 03806.0537

- b) detecting a complex formed between the nucleic acid and the probe.
- 15. The method of detection according to claim 14, wherein the probe is immobilized on a support.
- 16. A kit for detecting the nucleic acid according to claim 1, wherein the kit comprises
  - a) a nucleotide probe selected from the group consisting of 1) a nucleotide probe comprising at least 15 consecutive nucleotides of a nucleotide sequence of any one of SEQ ID NOs: 1-4, or a complementary nucleotide sequence thereof, 2) a nucleotide primer as in any one of claim 7 or 9, 3) a nucleotide probe comprising a nucleotide sequence of any one of SEQ ID NOs: 7-38, or a complementary nucleotide sequence thereof, and optionally.
  - b) reagents necessary for a hybridization reaction.
  - 17. The kit according to claim 16, wherein the probe is immobilized on a support.
- 18. A recombinant vector comprising the nucleic acid according claim 1.
  - 19. The vector according to claim 18, wherein the vector is an adenovirus.
  - 20. A recombinant host cell comprising the recombinant vector according to claim 19.
    - 21. A recombinant host cell comprising the nucleic acid according claim 1.
- 22. An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of any one of SEQ ID NO: 5 or 6.
  - 23. A recombinant vector comprising the nucleic acid according to claim 22.
  - 24. A recombinant host cell comprising the nucleic acid according to claim 22.
  - 25. A recombinant host cell comprising the recombinant vector according to claim 23.
    - 26. An isolated polypeptide selected from the group consisting of
    - a) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 5 or 6,
- b) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 5 or 6, and
  - c) a polypeptide homologous to a polypeptide comprising amino acid sequence of any one of SEQ ID NO: 5 or 6.

5



Attorney Docket No. 03806,0537

- 27. An antibody directed against the isolated polypeptide according to claim 26.
- 28. The antibody according to claim 27, wherein the antibody comprises a detectable compound.
  - 29. A method of detecting a polypeptide, wherein the method comprises
- a) contacting the polypeptide with an antibody according to claim 28; and
- b) detecting an antigen/antibody complex formed between the polypeptide and the antibody.
  - 30. A diagnostic kit for detecting a polypeptide, wherein the kit comprises
  - a) the antibody according to claim 28; and
- b) a reagent allowing detection of an antigen/antibody complex formed between the polypeptide and the antibody.
  - 31. A pharmaceutical composition comprising the nucleic acid according to claim 1 and a physiologically compatible excipient.
- 32. A pharmaceutical composition comprising the recombinant vector according to claim 23 and a physiologically compatible excipient.
  - 33. Use of a recombinant vector according to claim 18 for the manufacture of a medicament for the prevention and/or treatment of a subject affected by a dysfunction in the lipophilic subtance transport.
- 34. Use of an isolated ABCA12 polypeptide comprising an amino acid sequence of SEQ ID NO: 5 or 6 for the manufacture of a medicament intended for the prevention and/or treatment of a subject affected by a dysfunction in the lipophilic subtance transport or by a pathology located on the chromosome locus 2q34 such as for example the lamellar ichthyosis, the polymorphic congenital cataract, or insulin-dependant diabete mellitus.
- 35. A pharmaceutical composition comprising a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 5 or 6, and a physiologically compatible excipient.
  - 36. Use of an ABCA12 polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 5 or 6 for screening an active ingredient for the prevention or treatment of a disease resulting from a dysfunction in the lipophilic subtance transport or of a pathology located on the chromosome locus 2q34 such as for example the lamellar ichthyosis, the polymorphic congenital cataract, or insulin-dependant diabete mellitus.





### Attorney Docket No. 03806.0537

- 37. Use of a recombinant host cell expressing an ABCA12 polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 5 or 6, for screening an active ingredient for the prevention or treatment of a disease resulting from a dysfunction in the lipophilic subtance transport.
- 38. A method of screening a compound active on the transport of lipid substance, an agonist, or an antagonist of ABCA12 polypeptides, wherein the method comprises
  - a) preparing a membrane vesicle comprising ABCA12 polypeptide having SEQ ID NOs: 4 or 5 and a lipid substrate comprising a detectable marker;
- b) incubating the vesicle obtained in step a) with an agonist or antagonist candidate compound;
  - c) qualitatively and/or quantitatively measuring a release of the lipid substrate comprising the detectable marker; and
- d) comparing the release of the lipid substrate measured in step b) with a measurement of a release of a labeled lipid substrate by a membrane vesicle that has not been previously incubated with the agonist or antagonist candidate compound.
  - 39. A method of screening an agonist or an antagonist of ABCA12 polypeptides, wherein the method comprises
- a) incubating a cell that expresses at least a ABCA12 polypeptide having SEQ ID NOs: 4 or 5 with an anion labeled with a detectable marker;
  - b) washing the cell of step a) whereby excess labeled anion that has not penetrated into the cell is removed;
  - c) incubating the cell obtained in step b) with an agonist or antagonist candidate compound for the ABCA12 polypeptide;
    - d) measuring efflux of the labeled anion from the cell; and
  - e) comparing the efflux of the labeled anion determined in step d) with efflux of a labeled anion measured with a cell that has not been previously incubated with the agonist or antagonist candidate compound.
    - 40. An implant comprising the recombinant host cell according to claim 24.